Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave

Market Focus

07/15

On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.

The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \"inquiry received,\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.

The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \"1+6\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1130433920"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130433920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130433920?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130433920","market":"us","top_or_hot":-1,"title":"Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave","media":"Market Focus","content":"<p><p>On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.</p><p>The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.</p><p>The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-07-15 09:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.</p><p>The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.</p><p>The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1130433920","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130433920","pubTimestamp":1784080068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.The rally comes amid sustained momentum from the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提醒|DotBio常规交易上涨5.12%，A股IPO在港股回归潮中进入询价阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}